Abstract
Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Current Pharmaceutical Design
Title:Brain Targeting of siRNA via Intranasal Pathway
Volume: 21 Issue: 31
Author(s): Chandana Mohanty, Paromita Kundu and Sanjeeb K. Sahoo
Affiliation:
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Abstract: Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Export Options
About this article
Cite this article as:
Mohanty Chandana, Kundu Paromita and Sahoo K. Sanjeeb, Brain Targeting of siRNA via Intranasal Pathway, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191737
DOI https://dx.doi.org/10.2174/138161282131151013191737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Differential Scanning Calorimetry as a Tool to Investigate the Transfer of Anticancer Drugs to Biomembrane Model
Current Drug Targets Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Prediction of Bioactive Compound Pathways Using Chemical Interaction and Structural Information
Combinatorial Chemistry & High Throughput Screening Wound Healing Effect of an in Situ Forming Hydrogel Loading Curcumin-Phospholipid Complex
Current Drug Delivery Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Molecular Predictors of Drug-induced Prolongation of the QT Interval
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials
Current Drug Targets New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials The Thymus During HIV Disease: Role in Pathogenesis and in Immune Recovery
Current HIV Research Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Roles of Insulin Resistance, Endothelial Dysfunction and Lifestyle Changes in the Development of Cardiovascular Disease in Diabetic Patients
Current Drug Targets CD93: Recent Advances and Implications in Disease
Current Drug Targets Progress in the Diagnosis and Treatment of Pulmonary Aspergillosis
Current Respiratory Medicine Reviews Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy